ALX Oncology (ALXO) CEO Jason Lettmann awarded 912,000 stock options

Q: What insider transaction did ALXO report for CEO Jason Lettmann?

ALX Oncology reported that CEO and director Jason Lettmann received a stock option grant for 912,000 shares on January 26, 2026. The options are a right to buy common stock at a fixed exercise price of $1.48 per share .

Q: What are the key terms of Jason Lettmann’s ALXO stock option grant?

Jason Lettmann received a stock option to purchase 912,000 ALXO common shares at an exercise price of $1.48 per share. The option expires on January 25, 2036 , giving him a long-dated right to buy shares if conditions are met.

Q: How does the ALXO stock option granted to Jason Lettmann vest?

The option granted to Jason Lettmann vests in 48 equal monthly installments , starting on February 26, 2026 . This creates a four-year vesting schedule, aligning the award with continued service over time rather than vesting all at once.

Q: How many ALXO derivative securities does Jason Lettmann own after this transaction?

After the reported transaction, Jason Lettmann beneficially owns 912,000 derivative securities , all in the form of this stock option award. The filing shows these options as held with direct ownership , rather than through an indirect entity or trust.

Q: What is the nature of the security in Jason Lettmann’s ALXO Form 4 filing?

The security reported is a stock option (right to buy) ALX Oncology common stock. It allows Jason Lettmann to purchase up to 912,000 shares at a fixed price of $1.48 per share before its January 25, 2036 expiration date.

Q: Is Jason Lettmann’s ALXO stock option grant reported as direct or indirect ownership?

The Form 4 reports direct ownership of the stock option by Jason Lettmann . There is no indication in the footnotes that the award is held through a trust, LLC, or other indirect entity, and no disclaimer of beneficial ownership is provided.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

ALX Oncology Holdings Inc. granted its Chief Executive Officer and director Jason Lettmann a significant stock option award. On January 26, 2026, he received an option to purchase 912,000 shares of common stock at an exercise price of $1.48 per share, expiring January 25, 2036.

The option vests in 48 equal monthly installments beginning February 26, 2026, meaning the award vests gradually over four years as long as service conditions are met. Following this grant, Lettmann beneficially owns 912,000 derivative securities directly in the form of these stock options.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Lettmann Jason

Role CHIEF EXECUTIVE OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	912,000	$0.00	--

Holdings After Transaction: Stock option (right to buy) — 912,000 shares (Direct)

Footnotes (1)

[object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 01/28/2026 - 04:30 PM

FAQ

What insider transaction did ALXO report for CEO Jason Lettmann?

ALX Oncology reported that CEO and director Jason Lettmann received a stock option grant for 912,000 shares on January 26, 2026. The options are a right to buy common stock at a fixed exercise price of $1.48 per share.

What are the key terms of Jason Lettmann’s ALXO stock option grant?

Jason Lettmann received a stock option to purchase 912,000 ALXO common shares at an exercise price of $1.48 per share. The option expires on January 25, 2036, giving him a long-dated right to buy shares if conditions are met.

How does the ALXO stock option granted to Jason Lettmann vest?

The option granted to Jason Lettmann vests in 48 equal monthly installments, starting on February 26, 2026. This creates a four-year vesting schedule, aligning the award with continued service over time rather than vesting all at once.

How many ALXO derivative securities does Jason Lettmann own after this transaction?

After the reported transaction, Jason Lettmann beneficially owns 912,000 derivative securities, all in the form of this stock option award. The filing shows these options as held with direct ownership, rather than through an indirect entity or trust.

What is the nature of the security in Jason Lettmann’s ALXO Form 4 filing?

The security reported is a stock option (right to buy) ALX Oncology common stock. It allows Jason Lettmann to purchase up to 912,000 shares at a fixed price of $1.48 per share before its January 25, 2036 expiration date.

Is Jason Lettmann’s ALXO stock option grant reported as direct or indirect ownership?

The Form 4 reports direct ownership of the stock option by Jason Lettmann. There is no indication in the footnotes that the award is held through a trust, LLC, or other indirect entity, and no disclaimer of beneficial ownership is provided.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lettmann Jason

(Last)

(First)

(Middle)

C/O ALX ONCOLOGY HOLDINGS INC.

323 ALLERTON AVENUE

(Street)

SOUTH SAN FRANCISCO

94080

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
ALX ONCOLOGY HOLDINGS INC [ ALXO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CHIEF EXECUTIVE OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
01/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock option (right to buy)	$1.48	01/26/2026		A		912,000		⁽¹⁾	01/25/2036	Common Stock	912,000	$0	912,000	D

Explanation of Responses:

1. Shares subject to the option vest in 48 equal monthly installments beginning on February 26, 2026.

	/s/ Shelly Pinto, by power of attorney	01/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR